We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics- Hematology Division

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Novel T-Cell Test for SARS-CoV-2 Can Help Monitor Cellular Immunity Against COVID-19

By LabMedica International staff writers
Posted on 21 Jul 2021
Print article
Illustration
Illustration
A novel T-cell test for SARS-CoV-2 can help monitor cellular immunity against COVID-19 and offers greater detail to the immune status of long-haul patients.

Infectolab Americas (Oakdale, MN, USA) has validated a novel T-cell test for COVID-19 that uses technology based on stimulating antigen specific T-cells in vitro and enumerating the antigen specific T-cells to a given antigen. Studies on antigen specific SARS-CoV-2 T-cells have shown that testing for Interferon-γ and IL-2 release can provide important information about cellular immunity post-infection and vaccine efficacy. Recent studies have shown that six months post-infection Interferon-γ and IL-2 producing antigen specific T-cells were present in the patients. They showed that the severity of the disease appears to have played a role in the number of T-cells present six months post-disease.

The mRNA vaccine study conducted by Infectolab showed that three months post-mRNA vaccine antigen specific central memory T-cells and antigen specific TH-1 T-cells were present in the participants’ blood, indicating the potential of a long-term cellular memory response to the vaccine.

Infectolab’s SARS-CoV-2 T-cell test provides an insight into the T-cells of COVID-19 patients and vaccinated individuals. The test has 3-4-day turnaround time and offers comprehensive reporting that gives information about the amount of SARS-CoV-2 antigen specific TH-1 T-cells and central memory T-cells. Having a quick T-cell test available for COVID-19 infected patients and also a test where vaccinated people can find out how likely it is that they have developed cellular immunity in addition to humoral immunity, can help guide treatment and ease many concerns.

“The pandemic has been an extremely challenging time for all of us and Infectolab Americas is proud to be able to introduce a neat tool like this, that can help give us a better understanding of the immune system response to the infection and the vaccination for COVID-19,” said Dr. Felix Scholz, PhD, President of Infectolab Americas.

Related Links:
Infectolab Americas

New
Gold Supplier
Novel Corona Virus (SARS-CoV-2) Ag Rapid Test Kit
Novel Corona Virus (SARS-CoV-2) Ag Rapid Test Kit (Prepacked)
New
Autosampler
AS 110
New
CLIA Analyzer
MAGLUMI X8
New
POCT Analyzer
HTY-100 Plus POCT Analyzer

Print article

Channels

Molecular Diagnostics

view channel
Real-world data support the clinical utility of the Decipher Prostate Biopsy Genomic Test for determining prostate cancer treatment options (Photo courtesy of Clinical Lab Products)

Advanced Sequencing Techniques Determine Cancer Genome Variants in Young Patients

A recent paper described a three-platform sequencing approach, including whole genome (WGS), exome, and RNA sequencing, that was used to examine tumor and germline genomes from prospectively identified... Read more

Industry

view channel
Illustration

ELITechGroup Acquires Freezing Point Osmometry Provider GONOTEC

ELITechGroup (Puteaux, France) has acquired GONOTEC (Berlin, Germany), thus uniting two osmometry market leaders. The acquisition will also provides the industry with a full range of osmometry solutions... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.